Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
22.73
USD
|
-0.96%
|
|
+6.31%
|
-25.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
717.1
|
3,514
|
8,799
|
2,974
|
2,731
|
2,193
|
-
|
-
|
Enterprise Value (EV)
1 |
659.9
|
2,917
|
7,713
|
1,712
|
1,718
|
1,606
|
1,792
|
1,781
|
P/E ratio
|
-6.95
x
|
-22.7
x
|
-31.3
x
|
-5.66
x
|
-5.63
x
|
-4.43
x
|
-4.27
x
|
-4.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.6
x
|
60.6
x
|
266
x
|
57.1
x
|
75.3
x
|
32
x
|
37.1
x
|
18.9
x
|
EV / Revenue
|
15.3
x
|
50.3
x
|
233
x
|
32.8
x
|
47.4
x
|
23.5
x
|
30.3
x
|
15.3
x
|
EV / EBITDA
|
-6.55
x
|
-22.4
x
|
-29.6
x
|
-3.8
x
|
-3.39
x
|
-3.36
x
|
-3.25
x
|
-3.22
x
|
EV / FCF
|
-5.99
x
|
-54.5
x
|
-32.4
x
|
-4.94
x
|
-4.21
x
|
-4.17
x
|
-4.77
x
|
-5.12
x
|
FCF Yield
|
-16.7%
|
-1.83%
|
-3.08%
|
-20.3%
|
-23.7%
|
-24%
|
-21%
|
-19.5%
|
Price to Book
|
2.73
x
|
5.78
x
|
8.06
x
|
2.46
x
|
2.7
x
|
2.86
x
|
3.32
x
|
3.15
x
|
Nbr of stocks (in thousands)
|
48,882
|
64,594
|
74,419
|
85,234
|
89,555
|
96,475
|
-
|
-
|
Reference price
2 |
14.67
|
54.40
|
118.2
|
34.89
|
30.49
|
22.73
|
22.73
|
22.73
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
43.1
|
57.99
|
33.05
|
52.12
|
36.28
|
68.46
|
59.1
|
116.1
|
EBITDA
1 |
-100.8
|
-130.3
|
-261
|
-450.6
|
-506.3
|
-478.7
|
-551.5
|
-553.4
|
EBIT
1 |
-106.4
|
-136.6
|
-267.8
|
-458.2
|
-515.3
|
-504.9
|
-558.3
|
-573
|
Operating Margin
|
-246.78%
|
-235.51%
|
-810.37%
|
-879.04%
|
-1,420.51%
|
-737.5%
|
-944.76%
|
-493.66%
|
Earnings before Tax (EBT)
1 |
-99.53
|
-134.2
|
-267.9
|
-474.2
|
-481.2
|
-500.8
|
-536.3
|
-563.8
|
Net income
1 |
-99.53
|
-134.2
|
-267.9
|
-474.2
|
-481.2
|
-489.1
|
-530.1
|
-557
|
Net margin
|
-230.92%
|
-231.46%
|
-810.49%
|
-909.78%
|
-1,326.51%
|
-714.35%
|
-897.07%
|
-479.89%
|
EPS
2 |
-2.110
|
-2.400
|
-3.780
|
-6.160
|
-5.420
|
-5.134
|
-5.328
|
-5.417
|
Free Cash Flow
1 |
-110.2
|
-53.5
|
-237.8
|
-346.8
|
-408.1
|
-385.2
|
-375.6
|
-348
|
FCF margin
|
-255.7%
|
-92.25%
|
-719.41%
|
-665.46%
|
-1,124.94%
|
-562.65%
|
-635.51%
|
-299.86%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
12.58
|
11.25
|
14.03
|
13.27
|
13.57
|
12.61
|
13.59
|
11.99
|
-1.917
|
28.94
|
18.25
|
10.33
|
10.57
|
14.72
|
19.72
|
EBITDA
|
-
|
-
|
-
|
-103.6
|
-108.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-80.42
|
-144.2
|
-98.3
|
-105.5
|
-110.1
|
-112
|
-132.3
|
-131.1
|
-139.9
|
-114
|
-127.1
|
-139.2
|
-142.2
|
-141.5
|
-145.1
|
Operating Margin
|
-639.03%
|
-1,281.96%
|
-700.65%
|
-795.49%
|
-811.07%
|
-888.13%
|
-973.47%
|
-1,093.29%
|
7,297.44%
|
-394%
|
-696.67%
|
-1,348.46%
|
-1,344.82%
|
-961.45%
|
-735.43%
|
Earnings before Tax (EBT)
1 |
-81.24
|
-146.9
|
-100.7
|
-113.2
|
-113.4
|
-103.1
|
-123.7
|
-122.2
|
-132.2
|
-107.4
|
-122.4
|
-133.1
|
-137.1
|
-137.1
|
-139.9
|
Net income
1 |
-81.24
|
-146.9
|
-100.7
|
-113.2
|
-113.4
|
-103.1
|
-123.7
|
-122.2
|
-132.2
|
-107.4
|
-118.8
|
-130.2
|
-133.3
|
-137.1
|
-139.9
|
Net margin
|
-645.56%
|
-1,305.3%
|
-717.59%
|
-853.53%
|
-835.53%
|
-818.07%
|
-909.82%
|
-1,019.21%
|
6,894.16%
|
-371.3%
|
-650.83%
|
-1,261.22%
|
-1,260.34%
|
-931.34%
|
-709.12%
|
EPS
2 |
-1.090
|
-1.960
|
-1.330
|
-1.490
|
-1.380
|
-1.170
|
-1.400
|
-1.380
|
-1.460
|
-1.120
|
-1.224
|
-1.342
|
-1.361
|
-1.315
|
-1.268
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/9/23
|
2/22/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
57.2
|
597
|
1,086
|
1,262
|
1,012
|
587
|
401
|
412
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-110
|
-53.5
|
-238
|
-347
|
-408
|
-385
|
-376
|
-348
|
ROE (net income / shareholders' equity)
|
-36.3%
|
-33.7%
|
-
|
-41.7%
|
-42.1%
|
-68.1%
|
-78.6%
|
-137%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-33.7%
|
-34.1%
|
-57.2%
|
-115%
|
-153%
|
Assets
1 |
-
|
-
|
-
|
1,407
|
1,411
|
855.5
|
462
|
364.3
|
Book Value Per Share
2 |
5.380
|
9.410
|
14.70
|
14.20
|
11.30
|
7.960
|
6.860
|
7.210
|
Cash Flow per Share
2 |
-
|
-0.8900
|
-
|
-4.330
|
-4.440
|
-4.370
|
-2.740
|
-2.470
|
Capex
1 |
6.79
|
3.59
|
12.8
|
13.6
|
14
|
11.4
|
10.8
|
10.2
|
Capex / Sales
|
15.76%
|
6.18%
|
38.59%
|
26.01%
|
38.55%
|
16.72%
|
18.33%
|
8.77%
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
22.73
USD Average target price
70.72
USD Spread / Average Target +211.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.45% | 2.19B | | +51.85% | 57.87B | | +41.42% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|